A case report of a very late response to 5-azacytidine in a patient with lower risk myelodysplastic syndrome: Time to update treatment guidelines for lower risk patients

RATIONALE: The hypomethylating agent 5-azacytidine has been approved in Europe for patients with intermediate 2 and high (i.e., higher) risk myelodysplastic syndrome according to the International Prognostic Scoring System (IPSS). A total of 91% of all first responses in higher risk patients occur w...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Medicine (Baltimore)
Egile Nagusiak: Spetsieris, Nikolaos, Diamantopoulos, Panagiotis, Zervakis, Konstantinos, Giannakopoulou, Nefeli, Rougala, Niki, Garefalakis, Georgios, Skarlatou, Vasiliki, Viniou, Nora-Athina
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Wolters Kluwer Health 2018
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5944567/
https://ncbi.nlm.nih.gov/pubmed/29703015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000010505
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak